Company: PRME
Filing Date: 2025-11-07
Form Type: S-3ASR
Source: 0001628280-25-050428
Chunk: 48

Company: Prime Medicine, Inc.
Filing Date: 2025-11-07
Form: S-3ASR
Chunk 48
---
Jefferies”), dated November 3, 2023, relating to the sale of shares of our common stock, $0.00001 par value per share (“common stock”). In accordance with the terms of the sales agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $300,000,000 from time to time through Jefferies, acting as our sales agent. This prospectus covers the offer and sale by us of shares of our common stock having an aggregate offering price of up to $200,000,000 of the $300,000,000 authorized under the sales agreement. If we wish to offer and sell additional shares of our common stock under the sales agreement in excess of the $200,000,000 being registered under this prospectus, for up to an additional $100,000,000, we must file with the Securities and Exchange Commission (the “SEC”) one or more additional prospectus supplements to register under the Securities Act of 1933, as amended (the “Securities Act”), the offer and sale of any such additional shares of our common stock we wish to offer and sell from time to time under the sales agreement.

Our common stock is listed on The Nasdaq Global Market under the symbol “PRME.” On November 4, 2025, the closing sale price of our common stock on The Nasdaq Global Market was $4.30 per share.

Sales of our common stock, if any, under this prospectus will be made by any method permitted that is deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act. Jefferies is not required to sell any specific number or dollar amount of securities, but will act as a sales agent using commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreed terms between Jefferies and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.

Jefferies will be entitled to compensation under the terms of the sales agreement at a commission rate equal to 3.0% of the gross proceeds of any shares of common stock sold under the sales agreement. In connection with the sale of our common stock on our behalf, Jefferies will be deemed to be an “underwriter” within the meaning of the Securities Act and the compensation of Jefferies will be deemed to be underwriting commissions or discounts. See “ Plan of Distribution ” beginning on